Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure

4Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.
Get full text

Abstract

We present a case report of a neonate receiving raltegravir-based postnatal HIV prophylaxis after in utero dolutegravir exposure. High levels of raltegravir and dolutegravir can potentially cause bilirubin toxicity as they compete for albumin binding and follow the same metabolic pathway through UGT1A1. This case suggests delaying initiation of raltegravir-based postnatal prophylaxis by 24-48 hours after in utero dolutegravir exposure.

Cite

CITATION STYLE

APA

Jacobs, T. G., van Aerde, K. J., Colbers, A., & Burger, D. M. (2022). Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure. Pediatric Infectious Disease Journal, 41(2), 131–132. https://doi.org/10.1097/INF.0000000000003364

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free